ICAM1 and prostate carcinoma: When E2F1 is targeted knockdown by shRNA-E2F1, which does not affect expression and phosphorylation of NF-κB/p65 and IκBα, but facilitates NF-κB binding to the ICAM-1 promoter (Figure 3), ICAM-1 transcription and production are subsequently induced, resulting in antitumor immunity against prostate carcinoma cells.